AIDSWEEKLY Plus; Monday, December 25, 2000 & January 1, 2001
Prepared by AIDS Weekly editors from staff and other reports

These related developments were described in the December 6, 2000, issue of the Journal of the American Chemical Society and the December 29, 2000, issue of the Journal of Organic Chemistry. Both publications are peer-reviewed journals of the American Chemical Society.

The compounds, called guanidinoglycosides, are intended to prevent HIV from forming and spreading throughout the body, according to Yitzhak Tor, who led the research team at the University of California, San Diego. Chemically modified from existing antibiotics known as aminoglycosides, the new compounds target the genetic structure of the virus essential to its replication, he said.

Specifically, they target the "Rev" protein that is responsible for producing and spreading HIV infected cells. Without this protein, viral cells would be unable to reproduce and the disease would be disarmed, Tor said. By working with the virus's genetics, the researchers have found a place less prone to mutations that could lead to drug resistance, he added.

"If we can use drugs that prevent Rev from creating new viral cells, the HIV genetic material becomes useless," Tor said. "While numerous other groups explore more traditional approaches to anti viral therapy, we believe that certain sites - like the rev intersection site - are promising and underutilized targets for anti-HIV drug design."

Aminoglycoside antibiotics have not been used to treat HIV because of their side effects and inefficiency in preventing the spread of the virus, Tor said. Guanidino groups are more promising, he believes. But it will be years before human testing could begin.

"We think this is an important direction for HIV research," Tor said. "We hope these compounds can inhibit the interactions that allow the HIV to spread. This area is still in the dark ages, so there's plenty of opportunity for progress."

This article was prepared by AIDS Weekly editors from staff and other reports.

001225
AW001205

Copyright © 2000 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.